Chronic myelogenous leukemia (CML) arises from a genetic abnormality, the Philadelphia chromosome, that consists of reciprocal translocation of portions of human chromosomes 9 and 22. The fusion protein that results from this somatic cell translocation, called p210bcr/abl, is a protein kinase with abnormally high tyrosine kinase activity, a property shared with the v-abl viral oncogene product. The apparent abnormal level of tyrosine kinase activity of p210 is correlated with the occurrence of the disease in both chronic and acute stages, ultimately leading to abnormal numbers of myeloid cells. The overall goal of this project is to understand how the phosphorylation of the p210bcr/abl fusion protein relates to its functions, and how these phosphorylations and functions are altered in myeloid cells expressing p210bcr/abl compared to those on c-ABL or BCR proteins in normal myeloid cells. The initial goal is to identify and quantitate sites on the proteins that are phosphorylated in vivo, as they are found in human cell lines of myeloid lineage expressing p210bcr/abl. The functional relevance of these phosphorylations will be probed through mutagenesis of the corresponding sites on plasmids, followed by expression f the mutant proteins. The identity of the protein kinases involved in the functionally relevant phosphorylation events will be evaluated through substrate specificity analysis, stable complex formulation, and cell division cycle dependence.
The specific aims of this project are: 1. To determine the sites and extent of phosphorylations on the p210bcr/abl fusion protein compared to those on the BCR and c-ABL proteins in cells of myeloid lineage. 2. To analyze the function of the phosphorylation sites by examining the effects of mutations in those sites in c-abl and bcr/abl. 3. To identify the protein kinases responsible for the functional phosphorylations on BCR, c-ABL and p210bcr/abl. Regulation of p210bcr/abl activities, including DNA binding, tyrosine kinase, localization, and interactions with other proteins, appear to be regulated by phosphorylation. Understanding the regulation of the activities of the p210bcr/abl protein relative to that of the normal c- Abl and BCR proteins will give insight into the molecular basis of chronic myelogenous leukemia. Further, these findings may suggest targets for new chemo-therapeutic approaches to controlling CML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA064593-03
Application #
5207982
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Rossi, Ferdinand; Yozgat, Yasemin; de Stanchina, Elisa et al. (2010) Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 8:1271-83
Berger, Alice H; Niki, Masaru; Morotti, Alessandro et al. (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216-23
Guo, Tianhua; Hajdu, Mihai; Agaram, Narasimhan P et al. (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15:6862-70
Antczak, Christophe; Veach, Darren R; Ramirez, Christina N et al. (2009) Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett 19:6872-6
Kashiwada, Masaki; Cattoretti, Giorgio; McKeag, Lisa et al. (2006) Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5'-phosphatase are required for regulation of CD4+CD25+ T cell development. J Immunol 176:3958-65
Liang, Xiquan; Hajivandi, Mahbod; Veach, Darren et al. (2006) Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 6:4554-64
Janas, Justyna; Skowronski, Jacek; Van Aelst, Linda (2006) Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol 406:593-605
Zhao, Mingming; Janas, Justyna A; Niki, Masaru et al. (2006) Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol 26:2479-89
Oki, Shinji; Limnander, Andre; Yao, Pin Mei et al. (2005) Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. Cell Cycle 4:310-4
Wolff, Nicholas C; Veach, Darren R; Tong, William P et al. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105:3995-4003

Showing the most recent 10 out of 37 publications